PF-07038124

• UNSPSC Description:

  PF-07038124 is a PDE4 inhibitor with an IC50 of 0.5 nM for PDE4B2. PF-07038124 shows inhibitory activities against IL-13, IL4, and IFNγ (IC50=125, 4.1, 1.06 nM, respectively). PF-07038124 can be used for research of atopic dermatitis and plaque psoriasis[1][2].

• Target Antigen:

  Phosphodiesterase (PDE)

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/pf-07038124.html

• Solubility:

  10 mM in DMSO

• Smiles:

  CCCOC1=C(OC)C=CC(C2=CN=CC([C@@]3([H])CB(OC3)O)=C2)=C1

• Molecular Weight:

  327.18

• References & Citations:

  [1]Boron containing pde4 inhibitors.WO2020070651A1.|[2]Eichenfield LF, et al. Efficacy and Safety of PF-07038124 in Patients With Atopic Dermatitis and Plaque Psoriasis: A Randomized Clinical Trial. JAMA Dermatol. 2024 Feb 1;160(2):156-163.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  Phase 2

• CAS Number:

  2415085-44-6